Zydus Wellness Limited, the consumer wellness company behind brands such as Sugar Free and Glucon-D, reported a sharp contraction in earnings for FY26, with consolidated net profit plunging 47 per cent year-on-year to ₹197 crore, even as consolidated net sales climbed 46.4 per cent to ₹3,940 crore. The results, disclosed in a stock exchange filing on Monday, 18 May, highlight the cost burden of rapid inorganic expansion weighing on the company's bottom line.

Quarterly Performance

For the January–March 2025 quarter (Q4 FY26), consolidated net profit declined nearly 6 per cent year-on-year to ₹162 crore. However, consolidated revenue from operations surged 62.1 per cent to approximately ₹1,476 crore compared to the same quarter in the previous financial year — underscoring a widening gap between topline momentum and profitability.

What Drove the Revenue Jump

The company attributed the strong topline growth to contributions from newly acquired businesses, which added significant scale to its portfolio. Operating performance remained relatively stable, with EBITDA rising 34.2 per cent year-on-year to ₹509 crore during FY26. Nonetheless, profitability remained under pressure due to integration-related expenses and higher operational costs tied to those acquisitions.

Brand Highlights

Sugar Free maintained its dominance in the sugar substitute category with a market share of 96.1 per cent, while also expanding into adjacent categories through new launches including Sugar Free D'lite Choco Spread. Hydration brand Glucon-D retained segment leadership with a 58.9 per cent market share and extended its reach into performance hydration products.

Protein snacking brand RiteBite Max Protein continued to scale and improved profitability to near double-digit EBITDA margins, aided by new product introductions such as protein drinks and functional snack bars. In skincare, Everyuth held strong positions in scrubs and peel-off masks, while Nycil continued to lead the prickly heat powder category. The broader nutraceutical and wellness portfolio — including Nutralite and Complan — recorded steady momentum during the year.

Dividend and Shareholder Matters

The board of directors recommended a final dividend of ₹1.20 per equity share (face value ₹2) for FY26, subject to shareholder approval at the annual general meeting scheduled for 4 August.

What to Watch

The central question for investors is how quickly integration costs normalise as acquired businesses mature within the Zydus Wellness fold. With revenue scaling sharply and EBITDA expanding, the earnings trajectory will hinge on whether cost pressures ease in FY27 — or persist into another year of margin compression.